Automatic cell counter provides scientists with an automated and standardized option over the manual hemacytometer for routine cell counting
Nexcelom Bioscience, an emerging provider of devices and instruments for cell-based assays used in cancer research and drug discovery, has launched its Cellometer Model Auto T4 cell counter.
The Auto T4 automates cell counting, a traditionally manual process that is time-consuming, tedious and susceptible to operator judgment, all of which can ultimately affect sample quality and produce inaccurate results.
The Auto T4 has a small footprint of 3.5x4inches to optimise lab space and is very simple to operate.
Integral to the Auto T4 is the Cellometer patent-pending disposable counting chamber made of high quality plastic materials.
Samples are pipetted into the chamber and placed into the Auto T4, which connects to a computer via a USB cable.
Imaging software automatically measures cell concentration and viability.
Cells within a heterogeneous sample with various sizes and morphology can also be measured, providing data not obtained by traditional methods.
The disposable chamber handles sample loading easily, requires minimal sample (20 microlitres), and eliminates washing steps.
Since the sample is completely contained within the disposable chamber, the Cellometer Auto T4 is free of cross-contamination and clogging.
Numerous cell counting and viability experiments have been conducted with the Auto T4 in comparison with using manual hemacytometers.
Same cell concentration results were measured over a wide range of cell conditions.
Application notes with further details are available from Nexcelom Bioscience.
"Scientists at the NCI and NIH who were customers of our Cellometer plastic disposable hemacytometer products have expressed a strong desire to further simplify cell counting." said Jean Qiu, president of Nexcelom Bioscience.
"We have designed the Auto T4 to satisfy that need.
"We provide an automated cell counting solution that is small in footprint and simple to use.
"It is affordable by each laboratory.
"Our customers told us that cells should be counted when experimental procedure requires it, but not when a centralized instrument is available.
"Communication with customers is the key.
"Without their important feedback, Nexcelom wouldn't be the successful company that it is today".
JW Hodge, senior scientist and director of the Recombinant Vaccine Group at the National Cancer Institute said: "The Auto T4 is a fantastic machine that saves our lab a lot of time.
"It is simple to use and small".
Headquartered in Lawrence, MA, close to Boston's biotech hub, Nexcelom Bioscience is an emerging designer, manufacturer and marketer of novel devices and instruments for cell-based assays used in cancer research and drug discovery.
Developed per researchers' requests, Nexcelom's solutions automate time-consuming procedures, enabling scientists to focus less on the process and more on the research results.
Nexcelom's products are currently being used in the labs of leading pharmaceutical companies, Biotech organisations, universities and research institutions.
